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Abstract
Background: There is a high prevalence of  diabetes mellitus type-2 (T2DM) and osteoporosis are problems worldwide. In 
this study, we evaluated the correlation  between T2DM and bone turnover in diabetic obese postmenopausal Saudi women. 
Subjects and Methods: The present study included total of  65 T2-DM obese postmenopausal Saudi women, (36 uncon-
trolled, 29 controlled) .The following serum biochemical parameters   were evaluated [fasting blood glucose (FBG),total 
calcium (Ca), phosphorus (Pi), parathyroid hormone (PTH), 1,25-(OH)2Vitamin D3 ,osteocalcin (OC), procollagen (PICP) 
and cathepsin k (Cath K) ].
Results: Serum OC levels were significantly decreased in diabetic obese postmenopausal group compared to their respective 
healthy group (P < 0.004). PICP and Cath K were significantly elevated   in diabetic postmenopausal   group compared to 
the healthy group ( P < 0.024 & 0.001). A significant elevation in 1,25(OH)2  Vitamin D3, Ca and Pi levels in diabetic obese 
postmenopausal  patients group compared to the healthy group. However, a non-significant changes was observed in serum 
PTH level between different groups.
Conclusion: In this study, the changes in the biochemical parameters and bone turnover markers in obese women are strong 
risk factors for diabetes development that may contribute to osteopenia and osteoporosis. The study showed the strong ef-
fect of  T2DM on biochemical markers of  bone turnover in obese postmenopausal Saudi women.
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Type-2 diabetes mellitus (T2DM) is a worldwide pan-
demic and World Health Organization (WHO) predicts 
that the current figure of  170 million affected patients 
with diabetes will be more than double, to 370 million 
patients by the year 20301. Saudi Arabia is currently at 
the top of  the list in the middle east countries with the 
highest number of  estimated cases of  diabetes melli-
tus2. Multiple factors affected the lifestyle of  Saudi Ara-
bian population whith more tendence to western life 
style. The population of  Saudi Arabia with changes in 
lifestyle, reduction of  physical activity and high calorie 
snacks and foods have led to increased prevalence of  
obesity which led to type-2 diabetes, hyperlipidemia and 
infertility in women3. The prevalence of  type-2 diabe-
tes in Saudi Arabia is around 23.7% of  total population 
which is considered the highest  percentage in Asia4. 
Prevalence of  obesity is 39.3% among diabetes as com-
pared to 18.5% among non diabetics5. The metabolic 
disorders in diabetes may adversely affect bone mar-
row density (BMD) and increase the risk of  fractures. 
Patients with type 2 diabetes are at high risk of  bone 
fractures which may be explained by poor bone quality6.
Type 2-diabetes differs from type I ( IDDM) which oc-
curs in young age, there is absence of  insulin and its 
treated only with insulin injection.
The structure of  the  mature adult  skeleton is the re-
sult   of    different   cellular mechanisms. These are en-
dochondral and intramembranous ossification together 
with modeling and remodeling   on preformed surfac-
es. The interplay of  these mechanisms determines the 
form of  the adult   skeleton. Estrogen plays an impor-
tant role in these mechanisms. In normal individuals, 
bone mass increases during skeletal growth to reach a 
peak  at  the  beginning of   the  third  decade  and  at 
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this  point  bone  resorption and formation are equally 
balanced. Levels of  peak bone mass are strongly influ-
enced by genetic factors although diet and exercise also 
play a role7. Bone remodeling can be divided into the 
following phases: quiescent, activation, resorption, for-
mation, mineralization8.
Sharifi et al9 found that a higher level of  HbA1c, a 
marker of  blood glucose control, was related to lower 
lumbar spine density in diabetic women9.
The goal of  the present study to evaluate the impact 
of  type-ІІ diabetes mellitus on biochemical markers of  
bone turnover in obese postmenopausal Saudi women. 
This work is a  trail to set up measurements for some 
bone turnover markers in both obese postmenopausal 




Sixty five postmenopausal Saudi women with type 2 
diabetes mellitus (36 uncontrolled, 29 controlled) aged 
between (45- 57± 4.32) years old were randomly select-
ed from diabetic patients during their clinical visits to 
medical administration at king Abdul Aziz University, 
Jeddah,  Saudi  Arabia.  In  addition,  twenty  healthy 
apparent  volunteer subjects   matched age between 47- 
57 years served as control (group I).   Group Π: Dia-
betic patients were divided into two subgroups depend-
ing on their glycosylated hemoglobin level (HbA1c): 
Controlled DM, they are regularly checked every three 
months in diabetic center at King Abdulaziz University 
hospital. The blood sample was withdrawn from pa-
tients every visit (3 month) to check the blood glucose 
control, also the glycosylated hemoglobin (HbA1c) was 
measured in each blood sample for 3 consecutive  sam-
ples  and  uncontrolled  DM  subgroup:  Included  36 
postmenopausal diabetic patients.
Methods: 
The biochemical parameters in the serum [fasting blood 
glucose (FBG), calcium (Ca), phosphorus (Pi), parathy-
roid hormone (PTH), 1,25-(OH)2Vit.D3  ,osteocalcin 
(OC), procollagen (PICP) and cathepsin k (Cath K) ] 
were evaluated using kits from Biodiagnostic ,England.
Statistical Analysis: Statistical analyses were performed 
with SPSS statistical software   package (version, 15). 
Numerical data presented in the present study were ex-
pressed as mean value for each parameter ± it’s corre-
sponding standard deviation of  the  mean.  One  way 
analysis  of   variance  (ANOVA)  was  carried  out  to 
test  the significance of   difference between  groups 
mean  values  for  each  parameter.  For  all compar-
isons, P-values of  < 0.05 were considered statistically 
significant. Correlation coefficient study ˝r˝ was carried 
out to find out the relationships between parameters in 
the same group.
Results
Table (1) shows the   (mean values ± standard deviation 
) of  general characteristics for all the studied groups 
including: age, duration of  diabetes, BMI, fasting blood 
glucose, glycosylated hemoglobin, systolic and diastolic 
blood pressure.
Analysis of  data by ANOVA indicated a significant 
differences in mean values between groups for each 
of  BMI, fasting blood glucose, glycosylated hemoglo-
bin, systolic and diastolic blood pressure  ( P < 0.001, 
0.0001, 0.0001,0.032 and 0.022 respectively).
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Table 1: Mean values ± SD of (age, duration of diabetes, BMI, FBG, HbA1c, 
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51.30 ± 4.318 
( 45 – 60) 
 
50.00 ± 2.493 
(45 - 54) 
 
50.00 ± 2.493 










5.45 ± 0.948 
( 4 – 7) 
 
5.39 ± 1.536 







29.36 ± 2.186 
( 25.60 -31.90) 
 
28.38 ±3.365 
(25.1 - 36.20) 
 
30.81 ± 2.006 








4.00 ± 0.355 
( 3.24 – 4.51) 
 
5.63 ± 0.622 
(4.59 - 6.83) 
 
11.20 ± 4.958 








5.13 ± 0.539 
( 4.41 – 5.8) 
 
5.43 ± 0.327 
( 4.73 – 6.11) 
 
9.19 ± 2.076 









114.30 ± 15.458 
( 90.00 – 140) 
 
132.76 ± 30.579 
(90 – 190) 
 
130.47 ± 24.924 







77.10 ± 7.629 
( 62 – 93) 
 
78.41 ± 11.400 
(60 – 100) 
 





Results of  ANOVA indicated significant differences be-
tween groups in the value total Ca , Pi and 1,25(OH)2 
Vitamin D3 ( P < 0.024 , 0.0001 and 0.007 respectively). 
No significant difference was detected between normal 
and diabetic groups for PTH (Table, 2).
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Table 2. Mean values ± SD of calcium homeostasis markers ( total calcium, phosphorus,  
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2.62 ± 0.237 





















2.68 ± 0.572 




3.32 ± 0.195 



















































127.51 ± 54.298 













Table (3) shows the mean values of  bone formation 
markers (osteocalcin and procollagen type-α carboxy 
terminal propeptide ) and bone resorption marker 
(cathepsin k) .
Table 3. Mean values ± SD of biochemical markers of bone 
turnover including bone formation markers ( osteocalcin and 
procollagen type-α carboxy terminal propeptide) and bone 
resorption marker (cathepsin k) in  




































18.34 ± 5.571 
( 11.86 – 28.75) 
 
14.59 ± 3.981 
( 7.40 – 21.92) 
 
12.74 ± 4.187 










2.44 ± 4.846 
( 0.02 – 21.53) 
 
5.59 ± 11.451 
( 0.02 – 58.38) 
 
11.29 ± 14.799 






Cath k (pmol/L) 
 
109.85 ± 75.949 
( 19.81 – 236.12) 
 
204.76 ± 92.381 
(98.15–415.20) 
 
239.89 ± 129.252 





OC: Osteocalcin, PICP: Procollagen type-I carboxy terminal propeptide, Cath k: cathepsin k . Values between brackets represent the 
range of  individual data.
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Data obtained from ANOVA studies indicated signifi-
cant differences between groups mean  values  for  each 
of   OC,  PICP  and  Cath  k  (  P  <  0.004,  0.025, 
and  0.0001, respectively). Correlation studies showed 
that serum cathepsin k showed a significant positive 
correlation ( r : 0.614, P: 0.005) with procollagen in the 
normal group. While, correlation studies in controlled 
diabetic subgroup between blood pressure (systolic and 
diastolic ) with BMI showed a highly significant pos-
itive correlation ( r : 0.680, P: 0.0001 & r : 0.588, P: 
0.001). Diastolic blood pressure showed a significant 
negative correlation with blood glucose (r : -0.396, P: 
0.034) while, blood glucose showed significant positive 
correlation with glycosylated hemoglobin ( r :0.415, P: 
0.025). Procollagen type- α carbocxy terminal propep-
tide showed a significant negative correlation with dias-
tolic blood pressure ( r : - 0.402, P: 0.031) and showed 
a significant positive with calcium ( r : 0.374, P: 0.027) 
and a significant negative with parathyroid hormone ( 
r :-0.340, P: 0.046). On other hand, correlation coeffi-
cient between all studied variables in uncontrolled dia-
betic subgroup showed that blood glucose had a highly 
significant positive correlation with glycosylated hemo-
globin ( r : 0.696, P: 0.0001).
Duncan multiple range ˝r˝ for testing the significant 
difference between normal group and controlled   di-
abetic   subgroup   revealed   no   significant   differ-
ence   in   phosphorus, parathyroid hormone and active 
form of  vitamin D3. While, the mean value of  calcium 
was highly significant compared to normal group and 
controlled diabetic subgroup. However, for testing the 
significant difference between normal group and un-
controlled diabetic subgroup the data showed no signif-
icant difference in mean values of  calcium and parathy-
roid hormone. While, the mean value of  phosphorus 
and active form of  vitamin D3 was highly significant 
between the normal group and uncontrolled diabetic 
subgroup (Tables 4 – 7).
 
Table 4. One way analysis of variance (ANOVA) for testing the 




Groups Controlled Diabetic Uncontrolled diabetic 
Normal ** N.S 
Controlled Diabetic  N.S 
                   N.S: non-significant 
**     Very Significant at P < 0.01 
Table 5. One way analysis of variance (ANOVA) for testing the 
significance of differences between groups mean values of phosphorus. 
 
 




                        ***   Highly Significant at P < 0.001 
Groups Controlled Diabetic Uncontrolled diabetic 
Normal N.S *** 
Controlled Diabetic  *** 
Table 6. One way analysis of variance (ANOVA) for testing the 










Groups Controlled Diabetic Uncontrolled diabetic 
Normal N.S N.S 
Controlled Diabetic  N.S 
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Discussion:
Status of  vitamin D is very important in diabetic mel-
litus patients. Immense studies  showed  that  both 
healthy and  diabetic  subjects  had  a  seasonal  variation 
of  glycemic control. Currently, the evidence supporting 
that vitamin D level is important to regulate some path-
ways related to type 2 diabetes development10, due to 
vitamin D which is important for insulin synthesis and 
release. Since the activation of  inflammatory pathways 
interferes with normal metabolism and disrupts proper 
insulin signaling, it is hypothesized that vitamin D could 
influence glucose homeostasis by modulating inflamma-
tory response10. Type-Π diabetes development involves 
impaired pancreatic β- cell function, insulin resistance 
and inflammation. Although mechanistically unclear, it 
has been suggested that both environmental and genet-
ic factors seem to be involved in developing type-Π dia-
betes mellitus11,12. Moreover, it has been confirmed that 
vitamin D play an important role  in insulin sensitivity 
by controlling calcium flux through the membrane in 
both β-cells and peripheral insulin target tissue13.
The results obtained showed a tendency for obesity 
(BMI ≥ 30) among uncontrolled diabetic  women and 
overweight (25- 29.9 Kg/m2) among controlled diabet-
ics and undiabetic control women. The study confirmed 
an inverse association between vitamin D level and an-
thropometric measures of  body size in type-Π diabetic 
patients. The reason for this is that the body weight and 
body fat are inversely correlated with 25 (OH)D lev-
els across the spectrum of  body weight ranging from 
normal to obese14. This inverse association is related to 
the greater volume of  distribution for both vit-D and 
25(OH)D in tissue. Vitamin D appears to affect exclu-
sively the insulin response to glucose stimulation. The 
direct effect of  vitamin D may be mediated by binding 
of  its circulating active form, 1,25 (OH)2 D3 to the 
beta cell of  vitamin D receptor [ 1,25(OH)2 D3 , 159.16 
Table 7. One way analysis of variance (ANOVA) for testing the significance of differences 





                                      
 
                    **     Very Significant at P < 0.01 
Groups Controlled Diabetic Uncontrolled diabetic 
Normal N.S ** 
Controlled Diabetic  ** 
pmol/L ]. Vitamin D has a beneficial effect on insulin 
action either directly by stimulating the expression of  
insulin receptor thereby enhancing insulin responsive-
ness for glucose transport 15, or indirectly via its role 
in regulating extracellular calcium ensuring normal cal-
cium influx through cell membranes and  adequate in-
tracellular cytosolic calcium. However, the demonstra-
tion that 25(OH) D supplementation enhances insulin 
sensitivity and improves glucose homeostasis in type-Π 
diabetes patients is considered a great clinical interest16.
The result obtained in this study is that the higher level 
of  1,25 (OH)2 vitamin D3 in uncontrolled diabetic sub-
jects (159.16 pmol/L) with highest level of  PTH (67.27 
pg/ml) in the same group could be the major and novel 
finding of  this study as an independent predictor of  
metabolic syndrome (MS). This is because a previous 
study showed that metabolic syndrome (MS) was diag-
nosed in patients with at least 3 of  the following charac-
teristics (1) elevated fasting triglycerides, elevated blood 
pressure ( ≥ 130/85) and elevated fasting glucose ( ≥ 
5.6 mmol/L). The three characteristics are highly impli-
cated to all our subjects beside the elevation of  HbA1c 
and the phosphate (3.32 mmol/L). The result showed 
that postmenopausal  women with normal serum cal-
cium (2.62 ± 0.237 mmol/L) but inappropriately high 
PTH, had higher serum glucose, glycosylated hemoglo-
bin and BMI as well as with systolic and diastolic blood 
pressure.
The only bone resorption cathepsin k studied in this 
study project, showed highly significant increase (239.89 
pmol/L) in uncontrolled patients with type-Π diabetic 
compared with controlled diabetic subgroup (204.76 
pmol/L) and healthy control women (109.85 pmol/L). 
This is indicated that bone resorption in postmenopau-
sal Saudi women with type-Π diabetes mellitus whether 
controlled or uncontrolled are very high, which leads to 
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high risk of  fracture. The overall of  results and findings 
in this study confirmed the high link between deficiency 
of  vitamin D status, hyperparathyroidism and type-Π 
diabetic specifically in obese postmenopausal women 
which could lead to metabolic syndrome which is clus-
ter of  risk factors including abdominal obesity, insulin 
resistance, dyslipidemia, hyperglycemia and elevated 
blood pressure, which were found in our patients17.
Conclusion
The present study has demonstrated that bone prob-
lems is highly prevalent among  Saudi  obese  postmen-
opausal diabetic  women.  It  seems  obvious  that  fur-
ther studies are needed to address the best preventive 
practical measures to overcome osteoporosis in obese 
postmenopausal Saudi women.
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